<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02279433</url>
  </required_header>
  <id_info>
    <org_study_id>DS6051-A-U101</org_study_id>
    <nct_id>NCT02279433</nct_id>
  </id_info>
  <brief_title>A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b</brief_title>
  <official_title>A Phase 1/1B Multi-Center, Non Randomized, Open-Label, Multiple Dose First-In-Human Study Of DS-6051b, An Oral ROS1 And NTRK Inhibitor, In Subjects With Metastatic and/or Unresectable Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AnHeart Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AnHeart Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      DS-6051b is an orally administered inhibitor of the tyrosine kinases (ROS1) and neurotropic&#xD;
      tyrosine kinase receptors (NTRK). This phase 1 first-in-human study evaluates safety and&#xD;
      tolerability of DS-6051b in cancer subjects and identify a recommended phase 2 dose (RP2D).&#xD;
      In addition, this study will also assess the pharmacokinetic (PK)/pharmacodynamic (PD)&#xD;
      profiles and preliminary efficacy of DS-6051b.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Dose Escalation part (Part 1) of this study will evaluate safety and tolerability, and&#xD;
      determine the tentative RP2D. Plasma exposure of DS-6051a and the exposure - QT interval&#xD;
      prolongation relationship will also be assessed. Approximately 30 subjects with advanced&#xD;
      solid tumors harboring ROS1 or NTRK1, NTRK2, or NTRK3 rearrangement, neuroendocrine&#xD;
      carcinoma, or with advanced solid tumors and tumor-induced pain will be enrolled.&#xD;
&#xD;
      The Food Effect (FE) part of this study is to determine the effect of food on the PK of&#xD;
      DS-6051a following administration of a single oral dose of DS-6051b. The safety and&#xD;
      tolerability of DS-6051b administered with or without food will also be assessed.&#xD;
&#xD;
      After the safety profile of DS-6051b is adequately evaluated, the Dose Expansion part (Part&#xD;
      2) will be initiated to further assess the safety and tolerability, and preliminarily&#xD;
      evaluate the efficacy of DS-6051b at the tentative RP2D. Approximately 40 cancer subjects&#xD;
      carrying a ROS1 or NTRK1, NTRK2, or NTRK3 rearrangement will be enrolled.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">March 2019</completion_date>
  <primary_completion_date type="Actual">March 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Number of participants with dose-limiting toxicities</measure>
    <time_frame>within 21 days following the first dose of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor response</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Tumor response will be assessed using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax) for DS-6051a</measure>
    <time_frame>At Days 1 and 15 of Cycle 1 (21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum concentration (Tmax) for DS-6051a</measure>
    <time_frame>At Days 1 and 15 of Cycle 1 (21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve from time zero to t (AUC0-t) for DS-6051a</measure>
    <time_frame>At Days 1 and 15 of Cycle 1 (21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in QTc interval</measure>
    <time_frame>within 2 years</time_frame>
    <description>ECGs performed to assess QTc interval (ms) at baseline and on study treatment and at the end of treatment visit.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>DS-6051b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DS-6051b is orally administered as 50 mg and 200 mg capsules once daily on Days 1 to 21 of a 21-day cycle. Dose escalation in Part 1 will continue until tentative Recommended Part 2 Dose (RP2D) is determined. In Part 2 participants will receive the RP2D.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DS6051b</intervention_name>
    <description>DS-6051b 50 mg and 200 mg capsules for oral administration</description>
    <arm_group_label>DS-6051b</arm_group_label>
    <other_name>Investigational product</other_name>
    <other_name>DS-6051a (a free base of 6051b)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically confirmed diagnosis of advanced solid tumors that have&#xD;
             relapsed from or are refractory to standard treatment or for which no standard&#xD;
             treatment is available&#xD;
&#xD;
          2. Part 1 Dose Escalation subjects must meet 1 of the following criteria:&#xD;
&#xD;
               -  Solid tumors with documented ROS1, NTRK1, NTRK2, or NTRK3 rearrangement&#xD;
&#xD;
               -  Neuroendocrine tumors&#xD;
&#xD;
               -  Solid tumors with tumor-induced pain&#xD;
&#xD;
          3. Part 2 Dose Expansion subjects must meet 1 of the following criteria:&#xD;
&#xD;
               -  NSCLC with documented ROS1, NTRK1, NTRK2, or NTRK3 rearrangement&#xD;
&#xD;
               -  k-RAS wild-type CRC with documented NTRK1, NTRK2, or NTRK3 rearrangement&#xD;
&#xD;
               -  Other solid tumors with documented ROS1, NTRK1, NTRK2, or NTRK3 rearrangement&#xD;
&#xD;
               -  Pulmonary LCNEC;&#xD;
&#xD;
          4. Male or female ≥18 years of age&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group performance status 0 to 1&#xD;
&#xD;
          6. Adequate organ function&#xD;
&#xD;
          7. Adequate blood clotting function&#xD;
&#xD;
          8. Women of childbearing potential must have a negative pregnancy test&#xD;
&#xD;
          9. Willingness to provide archival tumor samples&#xD;
&#xD;
         10. Other inclusion criteria may apply&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hematological malignancies&#xD;
&#xD;
          2. Known positive HIV infection, or active hepatitis B or C infection&#xD;
&#xD;
          3. Comorbidity that would interfere with therapy&#xD;
&#xD;
          4. Receipt of an allogeneic bone marrow or allogeneic stem cell transplant&#xD;
&#xD;
          5. Concomitant medical condition that would increase the risk of toxicity, in the opinion&#xD;
             of the Investigator or Sponsor&#xD;
&#xD;
          6. History of myocardial infarction and unstable angina within 6 months before study drug&#xD;
             treatment; symptomatic congestive heart failure (Congestive Heart Failure New York&#xD;
             Heart Association Class III or IV); congenital long QT syndrome; or ventricular&#xD;
             arrhythmias defined as grade ≥2 according to NCI CTCAE, v4&#xD;
&#xD;
          7. Clinically active primary central nervous system tumors or brain metastases with the&#xD;
             exception of subjects with glioblastoma multiform that carry ROS1 rearrangement&#xD;
&#xD;
          8. Unresolved toxicities from previous anticancer therapy&#xD;
&#xD;
          9. Systemic treatment with anticancer therapy within 3 weeks before study drug treatment&#xD;
&#xD;
         10. Therapeutic radiation therapy or major surgery within 4 weeks before study drug&#xD;
             treatment or palliative radiation therapy within 2 weeks before study drug treatment&#xD;
&#xD;
         11. Participation in a therapeutic clinical study within 3 weeks for biological&#xD;
             treatments, and within 2 weeks or 5 half-lives, whichever is longer, for small&#xD;
             molecule agents, before study drug treatment&#xD;
&#xD;
         12. Concomitant treatment with strong inhibitors or inducers of CYP3A4 and P-glycoprotein&#xD;
&#xD;
         13. Clinically significant malabsorption syndrome or other gastrointestinal disease that&#xD;
             would impact drug absorption&#xD;
&#xD;
         14. QTcF values higher than 450 ms at screening&#xD;
&#xD;
         15. Breastfeeding&#xD;
&#xD;
         16. Other exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director Oncology</last_name>
    <role>Study Director</role>
    <affiliation>AnHeart Therapeutics Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HonorHealth Research Institute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chao Family Comprehensive Cancer Center of</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Inst.</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 15, 2014</study_first_submitted>
  <study_first_submitted_qc>October 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2014</study_first_posted>
  <last_update_submitted>September 18, 2020</last_update_submitted>
  <last_update_submitted_qc>September 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoplasms</keyword>
  <keyword>Lung Neoplasms</keyword>
  <keyword>Colorectal Neoplasms</keyword>
  <keyword>Neuroendocrine Tumors</keyword>
  <keyword>Pancreatic Neoplasms</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

